Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by UBS Group AG

UBS Group AG trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 17.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 256,624 shares of the company’s stock after selling 55,650 shares during the period. UBS Group AG owned approximately 0.56% of Amphastar Pharmaceuticals worth $6,872,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of AMPH. Dimensional Fund Advisors LP grew its holdings in shares of Amphastar Pharmaceuticals by 7.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,755,665 shares of the company’s stock worth $46,789,000 after acquiring an additional 128,781 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Amphastar Pharmaceuticals by 3.0% in the 3rd quarter. Marshall Wace LLP now owns 874,068 shares of the company’s stock worth $23,294,000 after acquiring an additional 25,383 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 12.7% in the 3rd quarter. Millennium Management LLC now owns 697,765 shares of the company’s stock worth $18,595,000 after acquiring an additional 78,781 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Amphastar Pharmaceuticals by 81.3% in the 2nd quarter. Qube Research & Technologies Ltd now owns 469,492 shares of the company’s stock worth $10,780,000 after acquiring an additional 210,511 shares during the last quarter. Finally, Algert Global LLC grew its holdings in shares of Amphastar Pharmaceuticals by 216.1% in the 3rd quarter. Algert Global LLC now owns 392,902 shares of the company’s stock worth $10,471,000 after acquiring an additional 268,612 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AMPH. Jefferies Financial Group restated a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Weiss Ratings lowered Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. Barclays reduced their target price on Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating for the company in a report on Wednesday, April 8th. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Finally, Piper Sandler restated a “neutral” rating and issued a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 11th. Seven research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $24.50.

Amphastar Pharmaceuticals Trading Up 3.6%

Amphastar Pharmaceuticals stock opened at $17.82 on Wednesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82. The company has a market capitalization of $785.68 million, a price-to-earnings ratio of 10.74, a PEG ratio of 2.79 and a beta of 0.97. Amphastar Pharmaceuticals, Inc. has a one year low of $16.65 and a one year high of $31.26. The company’s fifty day moving average price is $20.14 and its two-hundred day moving average price is $24.21.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.28). The business had revenue of $171.17 million for the quarter, compared to analyst estimates of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%. On average, analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.93 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.